Trials / Completed
CompletedNCT00143520
Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
A Randomized, Double-blind, Double-dummy, Placebo-controlled 26-week Dose-response Study of Rivoglitazone HCl (CS-011) With Active Comparator (Pioglitazone HCl) in Subjects With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 441 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a 6-month study to evaluate the effects of monotherapy with rivoglitazone, an insulin sensitizer, on glycemic control in newly identified type 2 diabetics or diabetics not adequately treated with other antidiabetic agents. The study tests rivoglitazone and uses a placebo and active treatment group for comparison.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivoglitazone | |
| DRUG | Pioglitazone | |
| DRUG | Placebo |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2005-12-01
- Completion
- 2005-12-01
- First posted
- 2005-09-02
- Last updated
- 2021-05-10
Locations
74 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00143520. Inclusion in this directory is not an endorsement.